earnings
confidence high
sentiment positive
materiality 0.65
Finch Therapeutics Q3 2021 net loss $10.0M; CP101 Phase 2 shows 80.3% cure rate
Finch Therapeutics Group, Inc.
2022-Q3 EPS reported
-$1.07
revenue$17,726,000
- Net loss of $10.0M for Q3 2021 (vs. $10.1M loss in Q3 2020); R&D expenses increased to $15.5M from $9.0M.
- CP101 Phase 2 open-label trial: 80.3% sustained clinical cure at 8 weeks, 78.8% at 24 weeks in recurrent CDI.
- Initiated enrollment in PRISM4 Phase 3 trial of CP101; topline data expected H1 2023.
- Cash and equivalents $149.2M as of Sept 30, 2021; expected to fund operations into mid-2023.
- CMO Zain Kassam stepped down; Debra Silberg named interim CMO; Marc Blaustein joined as COO; Al Hamood added to board.